Solentim & ATUM announce technology collaboration
Integrating Solentim’s VIPS™ hardware for isolating single cells with ATUM’s efficient Leap-In Transposase® expression technology, enable rapid, high expression, stable cell line development
About Solentim
Aaron Figg, Director
Solentim is a life sciences instruments company which enables customers to develop an increased number of new and better biopharmaceuticals by providing practical, innovative solutions to help with the challenges of drug discovery and development.
Commercial stable cell line development for biopharmaceutical production and gene therapy is a high value process which is inherently expensive and historically takes a significant amount of time. Solentim® has established itself over the past eight years as a significant leader and innovator of new products in the cell line development arena.
The Cell Metric® product range of bright field imaging stations has a large global installed base of customers, and is recognised as the leader for documenting proof of clonal origin for Master Cell Banks in IND filings to the medicines regulators.
Solentim’s second product range - an automated single cell cloning system called VIPS™ - combines single cell printing into microtiter plates with whole well imaging for clonality.
We help to optimise workflows
Providing solutions for customers working in cell line development in these areas…
Therapeutic Antibody Production
Customers who need to develop, bank and scale up stable cell lines for producing recombinant therapeutic monoclonal antibodies
Biosimilars and Biobetters
Customers developing stable cell lines which make equivalents (Biosimilars) or improved versions of existing blockbuster therapeutic antibodies where the patent has or will expire shortly
Gene Editing & Cell Engineering
Customers in drug discovery using targeted gene editing to make stable cell lines as cellular reagents for target validation, functional genomics and disease modelling
Gene Therapy & CAR-T
Customers involved in vector development who are making stable producer cell lines for virus production which will then be used to infect target cells
Antibody Discovery
Customers working with hybridomas and B cells to discover novel antibody sequences and produce diversity of antibodies. These groups may also be involved in the development of diagnostic antibodies
VIEW OUR WEBINAR
"How a Top-5 Pharma Doubled the Speed of Cell Line Development"
Latest News
Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development
NEWS – Bournemouth, UK – 14th January 2019: Solentim, a global leader in cell line development instrumentation, and bioengineering company ATUM, today announced a technology partnering and collaboration agreement. This
Solentim Strengthens Team | Claire Richards appointed Head of Biological Science
NEWS – Bournemouth, UK – 10th January 2019: Solentim, the innovator and leader in Cell Line Development instrumentation, is pleased to announce the appointment of Claire Richards as their new
Solentim exhibiting this January at PepTalk in San Diego, CA
NEWS - Bournemouth, UK – 3rd January 2019: Solentim, the innovator and leader in Cell Line Development instrumentation, is pleased to announce they will be exhibiting at the Annual PepTalk
Finding the right balance: digital biology versus smart, transformative automation
In this latest blog by Solentim’s Dr Ian Taylor, the advent of digital biology is discussed. This is compared and contrasted with smarter automation, transformative new biology and better control
Why is a clonally pure cell line so important in CRISPR research?
Never far from scientific and mainstream news, CRISPR is regularly hailed as one of the most important scientific discoveries of our time. With potential applications across wide-ranging fields from medicine
Solentim Wins Place in Deloitte UK Technology Fast 50
Aaron Figg & Ian Taylor at the Deloitte UK Technology Fast 50 Solentim named as one of the top 50 fastest growing UK technologies companies of
Solentim Wins Two Queen’s Awards for Enterprise
Aaron Figg, Dave Elverd, Mr (Ian) Angus Campbell (Her Majesty’s Lord-Lieutenant of Dorset), Ian Taylor, Sky Jiang Solentim’s business excellence and expertise in cell line development
The changing workflows of cell line development – Quality, not Quantity
Damp weather did little to suppress the energy in the rooms at last week’s 10th Annual BioProcessing Summit in Boston. There were over 1,000 delegates, including many from the US
Technology facilitating single cell cloning to help meet regulatory requirements
Patricia Fitzpatrick Diamond discusses recent technological advances aiding single cell cloning, including Solentim’s VIPS™, in GEN. To meet regulatory standards, recombinant proteins must be produced from a single cell line,
Janssen Pharma to present VIPS data at major conference
Customer data presentation at the Bioprocessing Summit in Boston NEWS - Bournemouth, UK – 30th July, 2018: Solentim, the innovator and leader in Cell Line Development instrumentation, is pleased to announce that